Tretinoin Gel
NDC Package 62032-413-20

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tretinoin gel is a medication used to treat acne. This formulation utilizes a gel delivery system. Marketed by Obagi Cosmeceuticals Llc, this product is identified by NDC 62032-413 and is authorized under FDA application NDA022070.

Identification & Billing

NDC Package Code
62032-413-20
Package Description
20 g in 1 TUBE
Product Code
62032-413
11-Digit Billing Format
62032041320
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Tretinoin
Non-Proprietary Name
Tretinoin
Substance Name
Tretinoin
Dosage Form
Gel - A semisolid3 dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion.4 A gel may contain suspended particles.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
TRETINOIN .05 g/100g
Pharmacologic Class
Usage Information
This medication is used to treat acne. It may decrease the number and severity of acne pimples and promote quick healing of pimples that do develop. Tretinoin belongs to a class of medications called retinoids. It works by affecting the growth of skin cells.

Regulatory & Marketing

Labeler Name
Obagi Cosmeceuticals Llc
Product Type
Human Prescription Drug
FDA Application #
NDA022070
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
06-19-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62032-413-20 identifies a specific commercial package of 20 g in 1 tube of Tretinoin, a human prescription drug labeled by Obagi Cosmeceuticals Llc. This gel is formulated for topical use and contains tretinoin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Obagi Cosmeceuticals Llc on June 19, 2014. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat acne. It may decrease the number and severity of acne pimples and promote quick healing of pimples that do develop. Tretinoin belongs to a class of medications called retinoids. It works by affecting the growth of skin cells.

How is this Obagi Cosmeceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62032041320. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62032-413-20
11-Digit CMS (5-4-2)
62032-0413-20

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.